Anlotinib plus Tislelizumab for Recurrent Metastatic Pancreas Ductal Adenocarcinoma with Germline BRCA2 Mutation: A Case and Literature Review

Abstract

Abstract Purpose While combined immunotherapy and anti-angiogenic therapy have demonstrated efficacy in renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma, the efficacy of first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with germline BRCA2 mutation remains unproven. Methods We described a BRCA2-mutated PDAC patient who presented with posterior cardiac metastasis eight months after surgery. We performed anlotinib plus tislelizumab on him for systemic therapy. Results After receiving four cycles of anlotinib combined with tislelizumab, abdominal CT scans indicated a complete response. The patient sustained this response for over 13 months on the combination regimen, with no reported adverse events. Conclusions The combination of tislelizumab and anlotinib may offer a viable therapeutic option for recurrent metastatic BRCA2-mutated PDAC.